MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that Chairman and Chief Executive Officer Vlad Vitoc, M.D. will present at the H.C. Wainwright & Co. 26th Annual Global Investment Conference taking place September 9–11, 2024, in New York City.
Dr. Vitoc’s presentation will reveal the latest clinical data from MAIA’s Phase 2 THIO-101 clinical trial of lead candidate THIO sequenced with the immune checkpoint inhibitor cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC) who failed 2 or more standard-of-care therapy regimens.
Conference details:
MAIA live presentation: | Tuesday, September 10, 2024, at 08:00 am ET* |
Live webcast: | |
Conference location: | Lotte New York Palace, New York City |
Conference registration: | Available on the conference website. |
1-on-1 meetings: | Requests available upon registration. |
Presentation slides: | ir.maiabiotech.com under Company Info: Presentations https://finance.yahoo.com/news/maia-biotechnology-present-phase-2-123000065.html |
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.